Tag Archives: Pharma

Congress’ Drug Addiction

Posted 2/26/16 on Employee Benefit News. The Congressional committee that recently demanded Martin Shkreli’s appearance must have hoped to spotlight a smug jerk responsible for the outrageous prescription drug pricing that we’re all up against. Of course there are lots of … Continue reading

Rate this:

Posted in Benefits, Brian Klepper, Conflicts of Interest, Health Care Cost, Market Dynamics, Medical Management, Policy/Law/Regulation, Politics, Quality | Tagged , , , , | 9 Comments

Why Does The FDA Approve Cancer Drugs That Don’t Work

BRIAN KLEPPER Posted 10/23/15 on The Health Care Blog A new study in JAMA Internal Medicine finds that two-thirds of cancer drugs considered by the US Food and Drug Administration (FDA) over the past five years were approved without evidence that … Continue reading

Rate this:

Posted in Analytics, Brian Klepper, Conflicts of Interest, Health Care Cost, Innovation, Life Sciences, Market Dynamics, Policy/Law/Regulation | Tagged , , | 3 Comments

The Goose and the Elephant

…striving for ever-higher earnings, drug companies large and small are relentlessly increasing pricing on old and new drugs because they can. They can because the industry successfully deployed lobbyists who persuaded a receptive Congress to heavily favor their interests, spinning laws away from regulatory controls and toward payment at any price. These circumstances, nurtured by pharma itself, make a 55-fold price increase possible and legal, if outrageous. And that’s the elephant in the room. Continue reading

Rate this:

Posted in General | Tagged , , , , , , | Leave a comment

What’s Behind the Growing Rate of Scientific Retractions?

Alison Bass First posted 8/10/11 on Alison Bass The retraction of studies in medical and scientific journals has surged in the last decade, according to separate analyses done by the Wall Street Journal and Retraction Watch. In its page-one article today, the Journal noted that … Continue reading

Rate this:

Posted in Analytics, Innovation, Life Sciences, Market Dynamics, Policy/Law/Regulation, Quality | Tagged , , , | Leave a comment

With Big Pharma on Campus, Who Will Look After the Public Interest?

Alison Bass First posted 8/3/11 on Alison Bass Medicare and social services for vulnerable Americans are not the only programs on the chopping block with Washington’s deal to raise the debt ceiling and cut trillions of dollars in government spending. … Continue reading

Rate this:

Posted in Innovation, Market Dynamics, Medical Management, Policy/Law/Regulation, Reform | Tagged , , | Leave a comment